Eurazeo (FR:RF) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kurma Partners has announced the first close at EUR 140 million for its new Biofund IV, with a target of EUR 250 million and plans to make 16 to 20 new investments in innovative therapeutics. The fund, which has already completed three investments, continues Kurma’s strategy of collaborating with academic and industry professionals to foster Europe’s health innovation ecosystem. With cornerstone investments from Eurazeo, Bpifrance, and CSL, and following successful exits from the Biofund III portfolio, the new fund demonstrates investor confidence in Kurma’s approach to healthcare innovation.
For further insights into FR:RF stock, check out TipRanks’ Stock Analysis page.